Evidence based medicine on the use of botulinum toxin for headache disorders

Journal of Neural Transmission

Volumn 115, Issue 4, 2008, Pages 647-651

  Schulte Mattler, W J ^a   Leinisch, E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Botulinum toxin; Evidence based medicine; Headache; Pain

Indexed keywords

BOTULINUM TOXIN A;

ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEADACHE AND FACIAL PAIN; HUMAN; MIGRAINE; NEUROTRANSMISSION; NOCICEPTION; PRIORITY JOURNAL; TENSION HEADACHE;

BOTULINUM TOXIN TYPE A; EVIDENCE-BASED MEDICINE; HEADACHE DISORDERS; HUMANS; NEUROMUSCULAR AGENTS;

EID: 42149139479     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-007-0832-3     Document Type: Article

References (49)

1. SS Arnon R Schechter TV Inglesby DA Henderson JG Bartlett MS Ascher E Eitzen AD Fine J Hauer M Layton S Lillibridge MT Osterholm T O'Toole G Parker TM Perl PK Russell DL Swerdlow K Tonat 2001 Botulinum toxin as a biological weapon: medical and public health management JAMA 285 1059 1070
2. SK Aurora M Gawel JL Brandes S Pokta AM Vandenburgh 2007 Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study Headache 47 486 499
3. N Barrientos P Chana 2003 Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study J Headache Pain 4 146 151
4. W Blersch WJ Schulte-Mattler S Przywara A May H Bigalke K Wohlfarth 2002 Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study J Neurol Sci 205 59 63
5. A Blumenfeld 2004 Botulinum toxin type A for the treatment of headache: pro Headache 44 825 830
6. AM Blumenfeld W Binder SD Silberstein A Blitzer 2003 Procedures for administering botulinum toxin type A for migraine and tension-type headache Headache 43 884 891
7. MF Brin S Fahn C Moskowitz A Friedman HM Shale PE Greene A Blitzer T List D Lange RE Lovelace 1987 Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm Mov Disord 2 237 254
8. DW Dodick A Mauskop AH Elkind R DeGryse MF Brin SD Silberstein 2005 Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study Headache 45 315 324
9. M Dong F Yeh WH Tepp C Dean EA Johnson R Janz ER Chapman 2006 SV2 is the protein receptor for botulinum neurotoxin A Science 312 592 596
10. PL Durham R Cady R Cady 2004 Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy Headache 44 35 42
11. Edlund W, Gronseth G, So Y, Franklin G (2004) Subcommittee for the Quality Standards Subcommittee and the Therapeutics and Technology Assessment Subcommittee. Clinical practice guideline process manual. Minneapolis: American Academy of Neurology, www.aan.com/globals/axon/assets/2535.pdf
12. L Edvinsson 2001 Sensory nerves in man and their role in primary headaches Cephalalgia 21 761 764
13. AH Elkind P O'Carroll A Blumenfeld R DeGryse R Dimitrova 2006 A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis J Pain 7 688 696
14. S Evers J Vollmer-Haase S Schwaag A Rahmann IW Husstedt A Frese 2004 Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study Cephalalgia 24 838 843
15. C Fernandes-de-las-Penas ML Cuadrado L Arendt-Nielsen DG Simons JA Pareja 2007 Myofascial trigger points and sensitization: an updated pain model for tension-type headache Cephalalgia 27 383 393
16. P Gazerani C Staahl AM Drewes L Arendt-Nielsen 2006 The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization Pain 122 315 325
17. MD Gill 1982 Bacterial toxins: a table of lethal amounts Microbiol Rev 46 86 94
18. PJ Goadsby L Edvinsson R Ekman 1990 Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 28 183 187
19. M Hallett 1999 One man's poison - clinical applications of botulinum toxin N Engl J Med 341 118 120
20. H Ishikawa Y Mitsui T Yoshitomi K Mashimo S Aoki K Mukuno K Shimizu 2000 Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles Jpn J Ophthalmol 44 106 109
21. HH Kramer C Angerer F Erbguth M Schmelz F Birklein 2003 Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin J Neurol 250 188 193
22. WS Lee SM Moussaoui MA Moskowitz 1994 Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva Br J Pharmacol 112 920 924
23. S Mahrhold A Rummel H Bigalke B Davletov T Binz 2006 The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves FEBS Lett 580 2011 2014
24. F Mancini R Zangaglia S Cristina MG Sommaruga E Martignoni G Nappi C Pacchetti 2003 Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism Mov Disord 18 685 688
25. NT Mathew BM Frishberg M Gawel R Dimitrova J Gibson C Turkel 2005 Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial Headache 45 293 307
26. WG Ondo KD Vuong HS Derman 2004 Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study Cephalalgia 24 60 65
27. M Padberg SF de Bruijn RJ de Haan DL Tavy 2004 Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial Cephalalgia 24 675 680
28. LA Phebus KW Johnson PW Stengel KL Lobb JA Nixon PA Hipskind 1997 The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs Life Sci 60 1553 1561
29. DE Rapp KW Turk GT Bales SP Cook 2006 Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder J Urol 175 1138 1142
30. M Relja AC Poole J Schoenen J Pascual X Lei C Thompson 2007 A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches Cephalalgia 27 492 503
31. JD Rollnik O Tanneberger M Schubert U Schneider R Dengler 2000 Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study Headache 40 300 305
32. RL Rosales H Bigalke D Dressler 2006 Pharmacology of botulinum toxin: differences between type A preparations Eur J Neurol 13 Suppl 1 2 10
33. F Sakai S Ebihara M Akiyama M Horikawa 1995 Pericranial muscle hardness in tension-type headache. A non-invasive measurement method and its clinical application Brain 118 2 523 531
34. G Schiavo M Matteoli C Montecucco 2000 Neurotoxins affecting neuroexocytosis Physiol Rev 80 717 766
35. WJ Schmitt E Slowey N Fravi S Weber JM Burgunder 2001 Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial Headache 41 658 664
36. P Schnider M Binder E Auff H Kittler T Berger K Wolff 1997 Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms Br J Dermatol 136 548 552
37. WJ Schulte-Mattler P Krack 2004 Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study Pain 109 110 114
38. WJ Schulte-Mattler T Wieser S Zierz 1999 Treatment of tension-type headache with botulinum toxin: a pilot study Eur J Med Res 4 183 186
39. WJ Schulte-Mattler O Opatz W Blersch A May H Bigalke K Wohlfahrt 2007 Botulinum toxin A does not alter capsaicin-induced pain perception in human skin J Neurol Sci 260 38 42
40. S Silberstein N Mathew J Saper S Jenkins 2000 Botulinum toxin type A as a migraine preventive treatment. For the BOTOX migraine clinical research group Headache 40 445 450
41. SD Silberstein SR Stark SM Lucas SN Christie RE Degryse CC Turkel 2005 Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial Mayo Clin Proc 80 1126 1137
42. SD Silberstein H Gobel R Jensen AH Elkind R Degryse JM Walcott C Turkel 2006 Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study Cephalalgia 26 790 800
43. T Sycha D Samal B Chizh S Lehr B Gustorff P Schnider E Auff 2006 A lack of antinociceptive or antiinflammatory effect of botulinum toxin a in an inflammatory human pain model Anesth Analg 102 509 516
44. JK Tsui A Eisen AJ Stoessl S Calne DB Calne 1986 Double-blind study of botulinum toxin in spasmodic torticollis Lancet 2 245 247
45. B Voller T Sycha B Gustorff L Schmetterer S Lehr HG Eichler E Auff P Schnider 2003 A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A Neurology 61 940 944
46. MJ Welch JR Purkiss KA Foster 2000 Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins Toxicon 38 245 258
47. K Wohlfarth H Goschel J Frevert R Dengler H Bigalke 1997 Botulinum A toxins: units versus units Naunyn Schmiedebergs Arch Pharmacol 355 335 340
48. N Yokosawa K Suga K Kimura K Tsuzuki N Fujii K Oguma H Yokosawa 1994 Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P Biochem Mol Biol Int 32 455 463
49. JA Zwart G Bovim T Sand O Sjaastad 1994 Tension headache: botulinum toxin paralysis of temporal muscles Headache 34 458 462